Fig. 1
Biomarker changes following the switch to intravitreal Faricimab over a nine-month period. This figure illustrates the longitudinal changes in key OCT biomarkers after switching to intravitreal Faricimab. Biomarkers assessed include (a) central retinal thickness (CRT), (b) intraretinal fluid (IRF), (c) subretinal fluid (SRF), (d) fibrovascular pigment epithelium detachment (fvPED), (e) subretinal hyperreflective material (SHRM), and (f) choroidal volume. Measurements were taken at baseline (mo0, first Faricimab injection), after three months (mo3, day of fourth Faricimab injection), and nine months post-switch (mo9). Pairwise comparisons were performed using the Friedman ANOVA test, with significant p-values indicated by asterisks (**** p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05)